AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

0:00-20:09

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.

Publisher

BioSpace

Published

September 30, 2026

Duration

20 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#astrazenecabuys #uniquredrops #yeardata #lifesciences

The Nile